Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Technical Advances in Esophageal Cancer Treatment
share announcement

Technical Advances in Esophageal Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 15 November 2024 | Viewed by 470

Special Issue Editor

Dr. Suzanne S. Gisbertz

E-Mail Website
Guest Editor
1. Department of Surgery, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2. Cancer Treatment and Quality of Life, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands
Interests: fluorescence guided surgery; artificial intelligence in surgery; robot-assisted surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Esophageal cancer is the 8th most common cancer worldwide, with more than 600.000 new cases each year. The standard curative treatment for patients diagnosed with esophageal carcinoma involves a combination of neoadjuvant chemoradiation therapy followed by an esophagectomy. The usefulness of esophagectomies, in terms of fluorescence, robot surgery, and artificial intelligence, is expected to emerge as improving surgical procedures and offering advantageous outcomes in terms of resectability, safety, and quality assurance. The utilization of approved surgical quality assurance (SQA) methods allows for the impartial evaluation of surgical performance, which can hold significance in terms of clinical outcomes.

We are pleased to invite you to submit high-quality articles or tools surrounding technical advances such as fluorescence angiography or translational research in esophageal cancer treatment, or studies that can be effectively employed in training, research, and quality improvement initiatives.

This Special Issue aims to present different technical advances in esophageal cancer treatment.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Surgical quality assurance, artificial intelligence, fluorescence imaging, indocyanine green, predicting response, endoscopic vacuum therapy, and extent of lymphadenectomy. 

We look forward to receiving your contributions. 

Dr. Suzanne S. Gisbertz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • artificial intelligence
  • predicting response
  • fluorescence
  • indocyanine green
  • SQA

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

16 pages, 1309 KiB  
Systematic Review
Long-Term Impact of Severe Postoperative Complications after Esophagectomy for Cancer: Individual Patient Data Meta-Analysis
by Davide Bona, Michele Manara, Gianluca Bonitta, Guglielmo Guerrazzi, Juxhin Guraj, Francesca Lombardo, Antonio Biondi, Marta Cavalli, Piero Giovanni Bruni, Giampiero Campanelli, Luigi Bonavina and Alberto Aiolfi
Cancers 2024, 16(8), 1468; https://doi.org/10.3390/cancers16081468 - 11 Apr 2024
Viewed by 331
Abstract
Background. Severe postoperative complications (SPCs) may occur after curative esophagectomy for cancer and are associated with prolonged hospital stay, augmented costs, and increased in-hospital mortality. However, the effect of SPCs on survival after esophagectomy is uncertain. Aim. To assess the impact of severe [...] Read more.
Background. Severe postoperative complications (SPCs) may occur after curative esophagectomy for cancer and are associated with prolonged hospital stay, augmented costs, and increased in-hospital mortality. However, the effect of SPCs on survival after esophagectomy is uncertain. Aim. To assess the impact of severe postoperative complications (SPCs) on long-term survival following curative esophagectomy for cancer, we conducted a systematic search of PubMed, MEDLINE, Scopus, and Web of Science databases up to December 2023. The included studies examined the relationship between SPCs and survival outcomes, defining SPCs as Clavien–Dindo grade > 3. The primary outcome measure was long-term overall survival (OS). We used restricted mean survival time difference (RMSTD) and 95% confidence intervals (CIs) to calculate pooled effect sizes. Additionally, we applied the GRADE methodology to evaluate the certainty of the evidence. Results. Ten studies (2181 patients) were included. SPCs were reported in 651 (29.8%) patients. The RMSTD overall survival analysis shows that at 60-month follow-up, patients experiencing SPCs lived for 8.6 months (95% Cis −12.5, −4.7; p < 0.001) less, on average, compared with no-SPC patients. No differences were found for 60-month follow-up disease-free survival (−4.6 months, 95% CIs −11.9, 1.9; p = 0.17) and cancer-specific survival (−6.8 months, 95% CIs −11.9, 1.7; p = 0.21). The GRADE certainty of this evidence ranged from low to very low. Conclusions. This study suggests a statistically significant detrimental effect of SPCs on OS in patients undergoing curative esophagectomy for cancer. Also, a clinical trend toward reduced CSS and DFS was perceived. Full article
(This article belongs to the Special Issue Technical Advances in Esophageal Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop